Journal of IiMER May 2025 BRMEC14 Session: Molecular Biology Elisa Oltra (Universidad Catolica de Valencia San Vicente Mártir, Spain) Dr Oltra will introduce talks on molecular mechanisms, biomarkers, and therapeutic strategies for ME/CFS. Alain Moreau (Université de Montréal / CHU Sainte-Justine, Canada) BRMEC14: From Discovery to Hope: Novel Insights into Biomarkers and Treatments for Myalgic Encephalomyelitis Professor Alain Moreau is a Full Professor at the Université de Montréal, with appointments in the Faculty of Dentistry and the Department of Biochemistry and Molecular Medicine. He leads the Molecular Genetics Laboratory of Musculoskeletal Diseases at CHU Sainte-Justine and directs the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis (ICanCME) Research Network. His research encompasses the molecular genetics of musculoskeletal conditions such as paediatric scoliosis and osteoarthritis, as well as complex adult diseases, including myalgic encephalomyelitis (ME/CFS). Professor Moreau’s work in ME/CFS centres on molecular profiling of patient samples to identify biomarkers and unravel disease mechanisms, with the ultimate aim of developing targeted treatments. At BRMEC14, he will present recent discoveries relating to novel biomarkers, including circulating microRNAs, and discuss how these findings are being translated into potential therapeutic approaches for ME/CFS. Professor Moreau will highlight how molecular profiling-particularly the analysis of circulating microRNAs-is advancing our understanding of ME/CFS pathophysiology and enabling the identification of distinct patient subgroups. These advances pave the way for precision medicine strategies, allowing treatments to be tailored to individual biological profiles. Anne Bertolotti (MRC Laboratory of Molecular Biology, Cambridge, UK) BRMEC14: Boosting Cellular Defence Mechanisms as a Treatment for Neurodegenerative Diseases Dr Anne Bertolotti specialises in cellular responses to misfolded proteins and chronic stress-processes increasingly recognised as relevant to ME/CFS. Her research focuses on the selective inhibition of phosphatases that regulate protein folding stress responses, which could provide insights into whether these protective pathways are disrupted in ME patients. At BRMEC14, Dr Bertolotti will discuss strategies to enhance cellular defences and improve protein homeostasis, with potential implications Invest in ME Research Page 17 of 43
19 Publizr Home